INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30100% above fair value
$121.16+3.09 (+2.62%)
Close on Nov 13, 2026Market cap $26.58BP/E –Yield –
Insmed profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Insmed's profit margin for the twelve months ending Sep 30, 2026 was -39.9%. For fiscal 2025 it was -210.5%, against -251.2% the year before. The highest annual figure on record is 1140.9% in fiscal 2009.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -210.5% | +40.7 |
| FY2024 | Dec 31, 2024 | -251.2% | −5.6 |
| FY2023 | Dec 31, 2023 | -245.6% | −49.3 |
| FY2022 | Dec 31, 2022 | -196.3% | +34.4 |
| FY2021 | Dec 31, 2021 | -230.6% | −51.8 |
| FY2020 | Dec 31, 2020 | -178.9% | +7.5 |
| FY2019 | Dec 31, 2019 | -186.4% | +3110.8 |
| FY2018 | Dec 31, 2018 | -3297.2% | −2809.6 |
| FY2013 | Dec 31, 2013 | -487.6% | +863.2 |
| FY2011 | Dec 31, 2011 | -1350.8% | −1257.8 |
| FY2010 | Dec 31, 2010 | -93.0% | −1233.9 |
| FY2009 | Dec 31, 2009 | 1140.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -19.1% | +240.8 |
| Q2 FY2026 | Jun 30, 2026 | -3.1% | +296.4 |
| Q1 FY2026 | Mar 31, 2026 | -53.5% | +223.0 |
| Q4 FY2025 | Dec 31, 2025 | -124.5% | +101.0 |
| Q3 FY2025 | Sep 30, 2025 | -260.0% | −23.9 |
| Q2 FY2025 | Jun 30, 2025 | -299.5% | +33.3 |
| Q1 FY2025 | Mar 31, 2025 | -276.4% | −68.4 |
| Q4 FY2024 | Dec 31, 2024 | -225.5% | −3.2 |
| Q3 FY2024 | Sep 30, 2024 | -236.0% | −35.0 |
| Q2 FY2024 | Jun 30, 2024 | -332.8% | −15.8 |
| Q1 FY2024 | Mar 31, 2024 | -208.1% | +36.9 |
| Q4 FY2023 | Dec 31, 2023 | -222.3% | +47.7 |
| Q3 FY2023 | Sep 30, 2023 | -201.0% | −7.4 |
| Q2 FY2023 | Jun 30, 2023 | -317.0% | −170.3 |
| Q1 FY2023 | Mar 31, 2023 | -245.0% | −66.8 |
| Q4 FY2022 | Dec 31, 2022 | -270.0% | −68.7 |
| Q3 FY2022 | Sep 30, 2022 | -193.6% | +47.4 |
| Q2 FY2022 | Jun 30, 2022 | -146.6% | +112.0 |
| Q1 FY2022 | Mar 31, 2022 | -178.2% | +49.7 |
| Q4 FY2021 | Dec 31, 2021 | -201.3% | +45.5 |
| Q3 FY2021 | Sep 30, 2021 | -241.1% | −95.2 |
| Q2 FY2021 | Jun 30, 2021 | -258.6% | −113.1 |
| Q1 FY2021 | Mar 31, 2021 | -227.9% | −47.8 |
| Q4 FY2020 | Dec 31, 2020 | -246.8% | −130.9 |
| Q3 FY2020 | Sep 30, 2020 | -145.9% | +10.2 |
| Q2 FY2020 | Jun 30, 2020 | -145.6% | +76.4 |
| Q1 FY2020 | Mar 31, 2020 | -180.0% | +158.5 |
| Q4 FY2019 | Dec 31, 2019 | -115.9% | +815.2 |
| Q3 FY2019 | Sep 30, 2019 | -156.1% | – |
| Q2 FY2019 | Jun 30, 2019 | -221.9% | – |
| Q1 FY2019 | Mar 31, 2019 | -338.6% | – |
| Q4 FY2018 | Dec 31, 2018 | -931.1% | – |
See a number that looks wrong?